A systematic overview of chemotherapy effects in Hodgkin's disease

Acta Oncologica

Volumn 40, Issue 2-3, 2001, Pages 185-197

  Brandt, L ^a   Kimby, E ^b   Nygren, P ^c   Glimelius, B ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; STREPTOZOCIN; VINBLASTINE; VINCRISTINE;

BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CARDIOTOXICITY; DRUG CHOICE; HODGKIN DISEASE; HUMAN; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SWEDEN; TREATMENT PLANNING; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS;

EID: 0034948535     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860151116240     Document Type: Review

References (116)

1. Clinical stage I and II Hodgkin's disease: Long-term results of therapy without laparotomy
2. Improved survival of Hodgkin's patients in South-East Netherlands since 1972
3. Staging for Hodgkin's disease
4. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European task force on lymphoma project on lymphocyte-predominant Hodgkin's disease
5. A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: A report from the Manchester lymphoma group
6. MOPP chemotherapy plus irradiation for Hodgkin's disease, stages IA to IIIB. Long-term results of the prospectice trial H72 (1972-1976, 334 patients)
7. Combined modality (ABVD plus radiotherapy) versus radiotherapy in the management of early stage (IIA) Hodgkin's disease with mediastinal involvement
8. Early stage Hodgkin's disease: Ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP
9. Clinical stages I and II Hodgkin's disease: A specifically tailored therapy according to prognostic factors
10. The EORTC trials for limited Hodgkin's disease
11. Experiences from the national Danish study group (LYGRA) with respect to diagnosis, classification and treatment of Hodgkin's disease
12. The evolution and summary results of the Stanford randomised clinical trials of the management of Hodgkin's disease 1962-1984
13. Four cycles of chemotherapy and regional radiation therapy for clinical early-stage and intermediate stage Hodgkin's disease
14. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987
15. A meta-analysis of stages I and II Hodgkin's disease
16. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early stage Hodgkin's disease: A meta-analysis of 23 randomised trials involving 3 888 patients
17. Stanford-Kaiser permanent G1 study for clinical stage I to IIA Hodgkin's disease: Subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation
18. 2 Cycles ABVD plus radiotherapy is more effective than radiotherapy alone in early stage HD - Results of the HD7 trial of the GHSG
19. Radiation therapy in clinical stage I and II Hodgkin's disease
20. Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index
21. Early stage Hodgkin's disease: Long term results with radiotherapy alone or combined radiotherapy and chemotherapy
22. Extended versus involved field irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease
23. Long-term results of curative irradiation in pathologically staged IA and IIA Hodgkin's disease
24. Stage IA and IIA supradiaphragmatic Hodgkin's disease: Prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation
25. Mantle irradiation alone for clinical stage I-II Hodgkin's disease: Long-term follow-up and analysis of prognostic factors in 261 patients
26. Treatment of early and intermediate stages of supradiaphragmatic Hodgkin's disease: The Swedish National Care Program experience
27. Stage IA-IIB Hodgkin's disease: Management and outcome of extensive thoracic involvement
28. Stage IA-IIB Hodgkin's disease: Staging and treatment of patients with large mediastinal adenopathy
29. Thoracic irradiation in Hodgkin's disease: Disease control and long-term complications
30. Massive mediastinal involvement in stage I-II Hodgkin's disease: Response to combined modality treatment
31. Second cancer after the treatment for Hodgkin's disease: A report from the international database on Hodgkin's disease
32. Risk of second malignancy after Hodgkin's disease in a large cohort of patients in Britain
33. Hodgkin's disease. Complications of therapy and excess mortality
34. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: Eight-year update of an Italian prospective randomized study
35. Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: Seven-year results of a prospective randomized trial
36. Involved field radiation is as effective as extended field radiation following chemotherapy for intermediate stage Hodgkin's disease expecting a reduction of long term side-effects: Interim analysis of the HD8 trial (GHSG)
37. Stage III Hodgkin's disease-long term results following chemotherapy, radiotherapy and combined modality therapy
38. The role of radiation therapy in Hodgkin's disease: Experience and controversy. The 54th annual Janeway lecture 1989
39. Stage III Hodgkin's disease: Improved survival with combined modality therapy as compared with radiation therapy alone
40. Randomised trial of chemotherapy versus chemotherapy plus radiotherapy for stage III-IVA & B Hodgkin's disease
41. Treatment selection for stage IIIA Hodgkin's disease patients
42. The treatment of stage IIIA Hodgkin's disease-total nodal irradiation versus combination chemotherapy: Either or neither
43. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease-long term results
44. Patterns of survival in patients with advanced Hodgkin's disease (HD) treated in a single centre over 20 years
45. Hodgkin's disease
46. A prognostic score for advanced Hodgkin's disease
47. Combination chemotherapy in advanced Hodgkin's disease. Induction and maintenance of remission
48. Maintenance chemotherapy for advanced Hodgkin's disease in remission
49. Fixed versus response-adapted MOPP/ABVD chemotherapy in Hodgkin's disease
50. Combined modality therapy of Hodgkin's disease: 10-Year results of National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial
51. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advanced Hodgkin's disease
52. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease
53. Extended field irradiation does not improve survival in stage IIIB-IV Hodgkin's disease (HD) in complete remission or good partial response: A randomised study from the GELA
54. Treatment of advanced-stage massive mediastinal Hodgkin's disease: The case for combined modality treatment
55. Improved survival in advanced Hodgkin's disease with the use of combined modality therapy
56. Role of radiation therapy in advanced Hodgkin's disease-as yet, an answer? Still a question?
57. Treatment outcome in Hodgkin's disease in patients above the age of 60: A population based study
58. Treatment of Hodgkin's disease: The Swedish National Care Program experience
59. A novel treatment for Hodgkins's disease in the elderly: P. Come
60. Curability of advanced Hodgkin's disease with chemotherapy: Long-term follow up of MOPP-treated patients at the National Cancer Institute
61. Twenty years of MOPP therapy for Hodgkin's disease
62. ChlVPP combination chemotherapy for Hodgkin's disease: Long term results
63. MVPP chemotherapy regimen for advanced Hodgkin's disease
64. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD
65. Hodgkin's disease and non-Hodgkin's lymphoma
66. The genetic origin of drug resistance in neoplasms: Implications for systemic therapy
67. Treatment of advanced-stage Hodgkin's disease: Alternating non cross-resistant MOPP/CABS is not superior to MOPP
68. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomised study by the Cancer and Leukemia Group B
69. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: Results of a British National Lymphoma Investigation Trial
70. A randomised study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial
71. Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: Results of a prospective clinical trial with 70 stage IIIB-IV patients
72. ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin's disease
73. An update of the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid programme
74. Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group
75. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results
76. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year results of the Intergroup trial
77. MOPP/ABV versus ABVD for advanced Hodgkin's disease-a preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC)
78. Results of a randomised trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease
79. Fourteen years clinical trial experience with the CHLVPP/EVA hybrid regimen as first line treatment for advanced Hodgkin's disease (HD)
80. Current clinical trials in Hodgkin's disease
81. BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease
82. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: A study of the German Hodgkin's lymphoma study group
83. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group
84. Dose escalated BEACOPP chemotherapy for advanced Hodgkin's diseae: Promising results of the fourth interim analysis of the HD9 trial
85. Interim analysis of the HD9 study of the German Hodgkin study group (GHSG) - BEACOPP is more effective than COPP/ ABVD in advanced stage Hodgkin's disease
86. Randomised comparison of COPP/ ABVD versus dose-and time-escalated COPP/ABVD with GM-CSF support for advanced Hodgkin's disease
87. Modern treatment of malignant lymphomas: A multidisciplinary approach. The Kaplan Memorial Lecture
88. Decreasing risk of leukemia with prolonged follow up after chemotherapy and radiotherapy for Hodgkin's disease
89. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD
90. Methyl-GAG, Ifosfamide, Methotrexate and Etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphomas
91. Conventional dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure
92. Early bone marrow transplantation in Hodgkin's disease
93. Single and double autotransplants for relapsing/refractory Hodgkin's disease: Results of two consecutive trials
94. Remission inversion and no transplant-related mortality - A single centre experience of autologous stem cell transplantation in malignant lymphoma
95. Autologous stem cell transplantation for refractory and relapsed Hodgkin's disease: Factors predictive of prolonged survival
96. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices
97. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell transplantation at the time of maximal response to conventional salvage therapy (Dexa-BEAM)
98. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: Is there a chance for cure?
99. Autotransplantation for relapsed or refractory Hodgkin's disease: Long-term follow up and analysis of prognostic factors
100. High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease-a pragmatic prognostic index
101. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV ± P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy
102. VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease
103. Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the autologous blood and marrow transplant registry
104. High-dose therapy and autologous stemcell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation
105. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial
106. High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD). Final results of a randomised GHSG and EBMT trial (HDR1)
107. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study
108. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease
109. Late psychosocial sequelae in Hodgkin's disease survivors: A French population based case-control study
110. Psychological distress after cancer cure: A survey of 459 Hodgkin's disease survivors
111. Socio-medical situation for long-term survivors of Hodgkin's disease: A survey of 459 patients treated at one institution
112. Reduced health-related quality of life among Hodgkin's disease survivors: A comparative study with general population norms
113. Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors
114. Late side effects common after treatment for Hodgkin's disease; muscular atrophy following radiotherapy a neglected risk
115. Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease